- Enters Strategic Collaboration for Development of Novel Infectious
Disease Diagnostic Platform -
WOBURN, Mass., Sept. 23 /PRNewswire/ -- U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics' DirectLinear Analysis(TM) technology (DLA) for the detection of a wide range of infectious organisms in a single molecular diagnostic test. A diagnostic platform based on DLA has the potential to provide information to physicians concerning pathogen identity, virulence and drug resistance within hours, as opposed to the multi-day techniques such as culturing, plating, and staining that are done today.
U.S. Genomics has invested in excess of $50 million in DLA technology, which integrates novel labeling strategies, advanced microfluidics and optical engineering to enable pathogens to be identified by rapidly analyzing individual DNA molecules present in a clinical sample. The technology is capable of simultaneously detecting a broad range of infectious organisms in a single diagnostic test. A diagnostic test based on DLA has the potential to provide clinicians and doctors' information important for patient health, such as which drugs a specific pathogen may be resistant to, and which drugs could be used for most effective patient treatment.
"We are very pleased to enter into this strategic relationship with
BD," said John J. Canepa, U.S. Genomics' CEO. "BD is the clear market
leader in clinical microbiology and their deep experience in product
development is an ideal complement to our innovative DLA technology and
strong research team. We share the goal of establishing a new, faster, more
accurate capability for microbial diagnostics, based on genotype, leading
|SOURCE U.S. Genomics|
Copyright©2008 PR Newswire.
All rights reserved